Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ERCC1 and Clinical Resistance to Platinum-Based Therapy

1 Sept 2005

Abstract excerpt

Praz and colleagues report in this issue on the relationship between the occurrence of a polymorphism of ERCC1 in tumor tissues of patients with colorectal cancer and the rate of disease response to the combination of oxaliplatin and 5-fluorouracil (1). This polymorphism is associated with reduced translation of the gene, and presumably, reduced DNA repair capability. Their report suggests that the ability of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Treatments and Studies
Share to DNA Repair Mechanisms
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16144907
DOI: 10.1158/1078-0432.ccr-05-1083

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ERCC1 and Clinical Resistance to Platinum-Based TherapyPMID 16144907Read ↗

Platinum Resistance: The Role of DNA Repair PathwaysSemantic proximity Read ↗

Genome-wide single-nucleotide resolution of oxaliplatin–DNA adduct repair in drug-sensitive and -resistant colorectal cancer cell linesSemantic proximity Read ↗

ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.Semantic proximity Read ↗

Testing the metal of ERCC2 in predicting the response to platinum-based therapy.Semantic proximity Read ↗

Platinum Resistance in Ovarian Cancer: Role of DNA RepairSemantic proximity Read ↗

Excision repair cross complementing-group 1: Gene expression and platinum resistance (Review) parameters in human breast cancerSemantic proximity Read ↗

Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiationSemantic proximity Read ↗

Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell LinesSemantic proximity Read ↗

Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapySemantic proximity Read ↗

Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cellsSemantic proximity Read ↗

Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.Semantic proximity Read ↗

The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.